Direct invasion to the colon by hepatocellular carcinoma: Report of two cases

Hirashita, Teijiro; Ohta, Masayuki; Iwaki, Kentaro; Kai, Seiichiro; Shibata, Kohei; Sasaki, Atsushi; Nakashima, Kimihiro; Kitano, Seigo; Von Weizsäcker, Fritz
July 2008
World Journal of Gastroenterology;7/28/2008, Vol. 14 Issue 28, p4583
Academic Journal
Case Study
Although hepatocellular carcinoma (HCC) is a common tumor, direct invasion of the gastrointestinal tract by HCC is uncommon. Recently, we encountered two cases of HCC with direct invasion to the colon. The first patient was a 79-year-old man who underwent transarterial chemo-embolization (TACE) for HCC 1.5 years prior to admission to our hospital. Computed tomography (CT) showed a 7.5-cm liver tumor directly invading the transverse colon. Partial resection of the liver and transverse colon was performed. The patient survived 6 mo after surgery, but died of recurrent HCC. The second patient was a 69-year-old man who underwent TACE and ablation for HCC 2 years and 7 months prior to being admitted to our hospital for melena and abdominal distension. CT revealed a 6-cm liver tumor with direct invasion to the colon. The patient underwent partial resection of the liver and right hemicolectomy. The patient recovered from the surgery. But, unfortunately, he died of liver failure due to liver cirrhosis one month later. Although the prognosis of HCC that has invaded the colon is generally poor due to the advanced stage of the disease, surgical resection may be a favorable treatment option in patients with a good general condition.


Related Articles

  • Cetuximab improved survival, response in KRAS wild-type colorectal liver metastases.  // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p23 

    The article reports on the improved overall survival (OS) and response rates in patients with unresectable KRAS wild-type liver metastases from colorectal cancer seen after addition of cetuximab to chemotherapy, which was able to deliver a three year OS of 30% while median survival was 24.4 months.

  • Hepatic resection for metastasis from colorectal cancer. Ji, Z.-L.; Peng, S.-Y.; Yuan, A.-J.; Li, P.-J.; Zhang, W.; Yu, Y. // Techniques in Coloproctology;Nov2004 Supplement 1, Vol. 8, ps47 

    Background Liver metastases from colorectal cancer are treatable and potentially curable when hepatic resection is applied. This paper is to illustrate surgical treatment of metastatic colorectal cancer in China. Patients and methods Between January 1993 and December 2002, 485 patients with...

  • Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer. Kaibori, Masaki; Iwamoto, Yoshinori; Ishizaki, Morihiko; Matsui, Kosuke; Yoshioka, Kazuhiko; Asano, Hiroaki; Kwon, A-Hon // Langenbeck's Archives of Surgery;Mar2012, Vol. 397 Issue 3, p373 

    Purpose: This study aimed to investigate the risk factors for early recurrence in patients who had undergone curative resection of colorectal liver metastases (CRLM) and to evaluate the outcome after recurrence. Methods: A total of 119 patients were divided into 2 groups: an early recurrence...

  • Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Inyoung Song; Hyunchul Rhim; Hyo Lim; Young-sun Kim; Dongil Choi // European Radiology;Nov2009, Vol. 19 Issue 11, p2630 

    The purpose of this study was to assess the feasibility, safety and efficacy of radiofrequency ablation (RFA) with the use of artificial ascites for hepatocellular carcinoma (HCC) adjacent to the diaphragm and gastrointestinal tract. One hundred forty-three patients with 181 HCCs who underwent...

  • MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Dengbo Ji; Zhiguo Chen; Ming Li; Tiancheng Zhan; Yunfeng Yao; Zhiqian Zhang; Jianzhong Xi; Li Yan; Jin Gu // Molecular Cancer;2014, Vol. 13 Issue 1, p1 

    Background Given the emerging role of microRNA in tumor disease progression, we investigated the association between microRNA expression, liver metastasis and prognosis of colorectal cancer. Methods Colorectal cancer tissues from patients with or without liver metastases were profiled to...

  • Synchronous Resection of Colorectal Primary Cancer and Liver Metastases. Yan, Tristan D.; Chu, Francis; Black, Deborah; King, Denis W.; Morris, David L. // World Journal of Surgery;Jul2007, Vol. 31 Issue 7, p1496 

    Patients with synchronous colorectal liver metastases are thought to have a less favorable prognosis than those with colorectal cancer alone. Surgical treatment options are controversial, be it synchronous resection or staged resection. This study compared the clinical, perioperative,...

  • Extended Resections of Liver Metastases from Colorectal Cancer. Jonas, S.; Thelen, A.; Benckert, C.; Spinelli, A.; Sammain, S.; Neumann, U.; Rudolph, B.; Neuhaus, P. // World Journal of Surgery;Mar2007, Vol. 31 Issue 3, p511 

    Indications for resection of liver metastases from colorectal cancer and surgical strategies are still under debate. We have retrospectively reviewed the outcome of 660 patients after 685 liver resections for metastases of colorectal cancer in our institution from 1988 to 2004. All surviving...

  • Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ruers, T.; Punt, C.; Van Coevorden, F.; Pierie, J. P. E. N.; Borel-Rinkes, I.; Ledermann, J. A.; Poston, G.; Bechstein, W.; Lentz, M. A.; Mauer, M.; Van Cutsem, E.; Lutz, M. P.; Nordlinger, B. // Annals of Oncology;Oct2012, Vol. 23 Issue 10, p2619 

    Background This study investigates the possible benefits of radiofrequency ablation (RFA) in patients with non-resectable colorectal liver metastases. Methods This phase II study, originally started as a phase III design, randomly assigned 119 patients with non-resectable colorectal liver...

  • Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. Chang, Li-Yuan; Lin, Yung-Chang; Chiang, Jy-Ming; Mahalingam, Jayashri; Su, Shih-Huan; Huang, Ching-Tai; Chen, Wei-Ting; Huang, Chien-Hao; Jeng, Wen-Juei; Chen, Yi-Cheng; Lin, Shi-Ming; Sheen, I-Shyan; Lin, Chun-Yen // OncoImmunology;Oct2015, Vol. 4 Issue 10, p00 

    Effector but not naive regulatory T cells (Treg cells) can accumulate in the peripheral blood as well as the tumor microenvironment, expand during tumor progression and be one of the main suppressors for antitumor immunity. However, the underlying mechanisms for effector Treg cell expansion in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics